{
    "Trade/Device Name(s)": [
        "CardioPhase hsCRP"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Products GmbH",
    "510(k) Number": "K232624",
    "Predicate Device Reference 510(k) Number(s)": [
        "K221119"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQD",
        "DCN"
    ],
    "Summary Letter Date": "November 27, 2023",
    "Summary Letter Received Date": "August 29, 2023",
    "Submission Date": "November 22, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.5270"
    ],
    "Regulation Name(s)": [
        "C-Reactive Protein Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "chemistry"
    ],
    "Analyte(s)": [
        "C-reactive protein (CRP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (heparin)",
        "Plasma (EDTA)"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "BN II System",
        "BN ProSpec System"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced immunonephelometry"
    ],
    "Methodologies": [
        "Immunoassay",
        "Nephelometry"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Siemens CardioPhase hsCRP reagent for quantitative CRP determination in serum and plasma using particle-enhanced immunonephelometry on BN II and BN ProSpec Systems.",
    "Indications for Use Summary": "Quantitative determination of C-reactive protein (CRP) in human serum and plasma (heparin, EDTA) to aid detection and evaluation of infection, tissue injury, inflammatory disorders, cardiovascular risk, and prognosis in stable coronary disease or acute coronary syndromes.",
    "fda_folder": "Immunology"
}